Want to see AORT full AI Analyst Report?
Top Page
Artivion
(NYSE:AORT)
Select Model
Select Model
Rating:56Neutral
Price Target:
$27.00
▲(6.80% Upside)
Action:Reiterated
Date:08/07/26
The score is primarily constrained by uneven financial quality—especially volatile and recently negative free cash flow—and a very high valuation (P/E 107.02). Offsetting these are steady revenue growth with strong gross margins and a constructive earnings-call outlook with reiterated 2026 guidance and key product/platform milestones, while technicals are only moderately supportive given the stock remains below longer-term moving averages.
Positive Factors
Platform and Portfolio Expansion
Full ownership of Endospan’s FDA‑approved NEXUS platform and associated pipeline creates a durable competitive advantage in aortic arch solutions. Owning the platform improves cross‑sell, simplifies commercialization, and enlarges the addressable market via multiple follow‑on PMA programs and modular product rollout.
Negative Factors
Free Cash Flow Volatility
Volatile and recently negative free cash flow reduces internal funding for commercialization and integration, increasing reliance on external financing. Persistent FCF weakness can constrain strategic flexibility, raise refinancing risk, and magnify the impact of adverse procedure volumes or working‑capital swings over a multi‑quarter horizon.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform and Portfolio Expansion
Full ownership of Endospan’s FDA‑approved NEXUS platform and associated pipeline creates a durable competitive advantage in aortic arch solutions. Owning the platform improves cross‑sell, simplifies commercialization, and enlarges the addressable market via multiple follow‑on PMA programs and modular product rollout.
Read all positive factors
Artivion (AORT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.40B
Dividend YieldN/A
Average Volume (3M)724.70K
Price to Earnings (P/E)―
Beta (1Y)0.68
Revenue Growth16.40%
EPS Growth85.99%
CountryUS
Employees1,800
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.06
Shares Outstanding48,756,220
10 Day Avg. Volume508,030
30 Day Avg. Volume724,698
Financial Highlights & Ratios
PEG Ratio-1.23
Price to Book (P/B)4.61
Price to Sales (P/S)4.69
P/FCF Ratio-2.27K
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$41.70Price Target Upside64.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.08
Revenue Forecast (FY)$486.22M
Artivion Business Overview & Revenue Model
Company Description
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in...
How the Company Makes Money
Artivion makes money primarily by selling medical devices and surgical implant products to hospitals and healthcare providers for use in vascular and cardiac surgery. Revenue is generated through (1) product sales of aortic and peripheral vascular...
Artivion Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call conveyed a constructive strategic and commercial story with multiple high‑impact milestones (AMDS PMA approval, Endospan/NEXUS acquisition, accelerating stent graft and On‑X growth) and reiterated full‑year guidance. These positives were offset by near‑term financial and operational headwinds: margin pressure, higher operating costs and amortization from the acquisition, negative free cash flow in the quarter driven by acquisition‑related cash outflows, and elevated leverage. Management emphasized that several lowlights are investment‑ or timing‑related and positioned as temporary as the business scales and NEXUS/AMDS commercialization progresses.Positive Updates
Total Revenue and EBITDA Growth
Total revenues of $125.8 million in Q2 2026, up 9% year-over-year (constant currency). Adjusted EBITDA increased ~7% to $26.4 million, with adjusted EBITDA margin of 21%.
Negative Updates
Margin and Expense Pressure
Adjusted EBITDA margin declined ~90 basis points year-over-year to 21%. Gross margin decreased to 64.0% from 64.7%, driven by unfavorable geographic mix and higher early Austin production costs.
Read all updates
Q2-2026 Updates
Positive
Negative
Total Revenue and EBITDA Growth
Total revenues of $125.8 million in Q2 2026, up 9% year-over-year (constant currency). Adjusted EBITDA increased ~7% to $26.4 million, with adjusted EBITDA margin of 21%.
Read all positive updates
Company Guidance
Management reiterated full-year 2026 guidance calling for adjusted constant-currency revenue growth of 7%–11% (reported revenue of $480M–$496M, with roughly a 1 percentage-point FX tailwind) and adjusted EBITDA of $92M–$99M, while assuming inconsequential U.S. NEXUS revenue in 2026 and expecting first meaningful NEXUS contributions in January 2027; they also expect to incur roughly $8M of Endospan-related expenses through 2026. Quarterly metrics cited include Q2 revenues of $125.8M (+9% Y/Y), adjusted EBITDA of $26.4M (+~7% Y/Y) and a 21% adjusted EBITDA margin (down ~90 bps Y/Y), free cash flow of negative $12M in Q2 (impacted by a $10.2M post-acquisition payment and $1.5M diligence/integration costs), cash of ~$77.3M, debt of ~$363M (net of $6.6M of loan origination costs) and a net leverage ratio of 3.1 as of June 30 (the $25M AMDS PMA milestone paid in July is excluded); management also flagged a difficult preservation-services comp in Q3 before normalization in Q4 and said 2027 results are expected to be EBITDA neutral as NEXUS ramps with R&D/clinical spending targeted at 7%–8% of sales.Artivion Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
58
Neutral
Cash Flow
45
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 471.47M | 441.33M | 388.54M | 354.00M | 313.79M | 298.84M |
| Gross Profit | 296.11M | 270.45M | 248.78M | 229.18M | 202.52M | 197.51M |
| EBITDA | 57.40M | 63.82M | 50.97M | 26.79M | 25.68M | 26.04M |
| Net Income | -3.17M | 9.77M | -13.36M | -30.69M | -19.19M | -14.83M |
Balance Sheet | ||||||
| Total Assets | 1.07B | 884.80M | 789.10M | 792.40M | 762.80M | 793.05M |
| Cash, Cash Equivalents and Short-Term Investments | 77.32M | 64.91M | 53.46M | 58.94M | 39.35M | 55.01M |
| Total Debt | 407.97M | 292.04M | 362.26M | 358.34M | 356.83M | 362.04M |
| Total Liabilities | 626.35M | 436.56M | 512.90M | 510.62M | 478.47M | 492.32M |
| Stockholders Equity | 445.58M | 448.23M | 276.20M | 281.78M | 284.33M | 300.73M |
Cash Flow | ||||||
| Free Cash Flow | -10.91M | -911.00K | 11.05M | 11.39M | -15.87M | -15.68M |
| Operating Cash Flow | 39.96M | 38.13M | 22.24M | 18.82M | -5.15M | -2.58M |
| Investing Cash Flow | -175.03M | -42.04M | -28.19M | -502.00K | -10.71M | 5.66M |
| Financing Cash Flow | 159.35M | 13.03M | 2.20M | 865.00K | -1.64M | -12.22M |
Artivion Technical Analysis
Positive
25.28
Price Trends
24.01
Positive
27.83
Positive
35.20
Negative
Market Momentum
1.00
Negative
63.30
Neutral
81.65
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AORT, the sentiment is Positive. The current price of 25.28 is below the 20-day moving average (MA) of 26.60, above the 50-day MA of 24.01, and below the 200-day MA of 35.20, indicating a neutral trend. The MACD of 1.00 indicates Negative momentum. The RSI at 63.30 is Neutral, neither overbought nor oversold. The STOCH value of 81.65 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AORT.
Artivion Risk Analysis
Artivion disclosed 33 risk factors in its most recent earnings report. Artivion reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Artivion Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $4.45B | 23.41 | 15.41% | ― | 12.39% | ― | |
68 Neutral | $2.67B | -71.21 | -17.88% | ― | 23.57% | -543.50% | |
63 Neutral | $851.55M | -55.77 | -8.23% | ― | 15.30% | 40.66% | |
56 Neutral | $1.40B | -476.68 | -0.71% | ― | 16.40% | 85.99% | |
55 Neutral | $423.62M | -6.63 | -14.05% | ― | 2.99% | 51.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.35B | -197.83 | -0.69% | ― | 1.60% | 98.56% |
* Healthcare Sector Average
AORT
Artivion
29.14
-13.67
-31.93%
IART
Integra Lifesciences
18.34
4.15
29.25%
OFIX
Orthofix Medical
10.34
-3.89
-27.34%
AXGN
AxoGen
48.73
33.80
226.39%
LIVN
LivaNova
82.22
28.50
53.05%
SIBN
SI-Bone
18.93
3.47
22.45%
Artivion Corporate Events
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Artivion Completes Strategic Acquisition of Endospan Platform
Positive
May 18, 2026
On May 18, 2026, Artivion completed the acquisition of its long-time partner Endospan, exercising an option agreement first signed in 2019 and later amended. Through its Singapore subsidiary, Artivion paid a net upfront purchase price of about $13...
Executive/Board ChangesShareholder Meetings
Artivion Shareholders Back Board, Pay and Auditor Choices
Positive
May 15, 2026
At Artivion’s 2026 Annual Meeting of Stockholders held on May 12, 2026, shareholders re-elected all nominated directors to serve until the next annual meeting or until their successors are chosen. This continuity on the board signals investo...
Business Operations and StrategyFinancial DisclosuresM&A TransactionsProduct-Related Announcements
Artivion Acquires Endospan to Expand Aortic Arch Portfolio
Positive
May 7, 2026
On May 7, 2026, Artivion reported first-quarter 2026 revenue of $116.3 million, up 18% year over year on a GAAP basis, with net income of $1.4 million and a 26% increase in adjusted EBITDA to $22.1 million. Management cited strong growth in stent ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.